

**Media Release, March 14, 2013**

## **BB Biotech AG completed its current share buyback program**

On March 13, 2013, BB Biotech AG completed its current share buyback program which was initiated on March 19, 2012. During this period a total of 1 150 000 registered shares were bought back through the second trading line.

### **For further information:**

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland  
Thomas Egger, Tel. +41 44 267 67 00, [teg@bellevue.ch](mailto:teg@bellevue.ch)

[www.bbbiotech.com](http://www.bbbiotech.com)

### **Company profile**

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector with CHF 1.4 billion in assets under management. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

### **Disclaimer**

This release contains forward-looking statements and expectations as well as assessments, beliefs and assumptions. Such statements are based on the current expectations of BB Biotech, its directors and officers, and are, therefore, subject to risks and uncertainties that may change over time. As actual developments may significantly differ, BB Biotech and its directors and officers accept no responsibility in that regard. All forward-looking statements included in this release are made only as of the date of this release and BB Biotech and its directors and officers assume no obligation to update any forward-looking statements as a result of new information, future events or other factors.